Evidence map›Paper›PMID 21967903›Full record

ArticleExperimental physiology2012

Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury.

Yanfei Qi, Hongwei Li, Vinayak Shenoy, Qiuhong Li, Fong Wong, Ling Zhang, Mohan K Raizada, Colin Sumners, Michael J Katovich

Open access · bronzeAbstract read
In one paragraph

Article in Experimental physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. The Angiotensin ATPharmacological reviews · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Nicotine and the renin-angiotensin system.American journal of physiology. Regulatory, integrative and comparative physiology · 2018
    Review
  17. Review
  18. Article
  19. Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer.Journal of experimental & clinical cancer research : CR · 2017
    Article
  20. Anti-fibrotic Potential of ATFrontiers in pharmacology · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yanfei QiDepartment of Pharmacodynamics, University of Florida, SW 1600 Archer Road, Gainesville, FL 32610, USA.
Hongwei Li
Vinayak Shenoy
Qiuhong Li
Fong Wong
Ling Zhang
Mohan K Raizada
Colin Sumners
Michael J Katovich
Southern Medical University · CNUniversity of Florida · USOphthalmology Associates (United States) · US

Funding

CVD protection mechanisms involving ACE2/Ang-(1-7) axisR01HL056921 · NHLBI · UNIVERSITY OF FLORIDA · PI RAIZADA, MOHAN K. · 1996 to 2015
$9.2M
Angiotensin-Converting Enzyme2 in Vascular Endothelial FunctionR01HL102033 · NHLBI · UNIVERSITY OF FLORIDA · PI RAIZADA, MOHAN K. · 2010 to 2019
$4.3M
NHLBI NIH HHS R01 HL056921NHLBI NIH HHS R01 HL102033
6 · The paper itself

Abstract

We hypothesized that moderate cardiac-selective overexpression of the angiotensin II type 2 receptor (AT2R) would protect the myocardium from ischaemic injury after a myocardial infarction (MI) induced by coronary artery ligation. For in vitro studies, adenoviral vector expressing genomic DNA of AT2R and enhanced green fluorescence protein (EGFP) was used to overexpress AT2R in rat neonatal cardiac myocytes. Expression of AT2R, measured by real-time PCR and immunostaining, demonstrated efficient transduction of AT2R in a dose-dependent pattern. The AT2R constitutively induced apoptosis in rat neonatal cardiac myocytes in dose-dependent patterns. For in vivo studies, 4 × 10(10) vector genomes (vg) of recombinant adeno-associated virus serotype 9 (rAAV9)-chicken β actin promoter-AT2R was injected into the left ventricle of 5-day-old Sprague-Dawley rats. At 6 weeks of age, hearts were harvested and expression of AT2R determined by real-time PCR and Western blotting. Expression was increased onefold over control hearts, and no apoptosis was detected. Two subsequent in vivo studies were performed. In a prevention study, 4 × 10(10) vg of rAAV9-CBA-AT2R was injected into the left ventricle of 5-day-old Sprague-Dawley rats and MI was induced at 6 weeks of age. For a post-treatment study, 4 × 10(10) vg of rAAV9-CBA-AT2R was administrated to the peri-infarcted myocardium area immediately after MI in 6-week-old animals. For both in vivo studies, cardiac functions were assessed using echocardiography and haemodynamic measurements 4 weeks after coronary artery ligation. In the in vivo studies, the rats subjected to MI showed significant decreases in fractional shortening and rate of change of left ventricular pressure, with increased left ventricular end-diastolic pressure and ventricular hypertrophy. For the prevention study, the moderate cardiac-selective overexpression of AT2R attenuated these MI-induced impairments and also caused a decrease in ventricular wall thinning. In the post-treatment study, the overexpression of AT2R partly reversed the MI-induced cardiac dysfunction. Myocardial infarction also induced the upregulation of angiotensin II type 1 receptor, angiotensin-converting enzyme and collagen I mRNA expression, all of which were attenuated by the overexpression of AT2R. It is concluded that moderate cardiac-selective overexpression of AT2R protects heart function from ischaemic injury, which may be mediated, at least in part, through modulation of components of the cardiac renin-angiotensin system and collagen levels in the myocardium.

Indexed as

AnimalsApoptosisHeart VentriclesHypertrophy, Left VentricularMaleMyocardial InfarctionMyocytes, CardiacRatsRats, Sprague-DawleyReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemReperfusion InjuryRNA, MessengerVentricular RemodelingReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2RNA, Messenger

Identifiers

PMID21967903
PMCPMC3619662
OpenAlexW2160638998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.